FB23-2 manufacturers
- FB23-2
-
- $32.00 / 1mg
-
2025-11-11
- CAS:2243736-45-8
- Min. Order:
- Purity: 98.00%
- Supply Ability: 10g
|
| Product Name: | FB23-2 | | Synonyms: | FB23-2;FB23-2(FTO Demethylase inhibitor FB23-2);Benzamide, 2-[[2,6-dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxy-;FB23-2，1.5g;2-[[2,6-Dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxybenzamide;FB23 2,AML,Apoptosis,leukemia,acute,anti-proliferation,Inhibitor,FB232,m6A,myeloid,mRNA,inhibit,FB23-2,demethylase,FB-23-2;2-((2,6-Dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)-N-hydroxybenzamide;FB23-2, 10 mM in DMSO | | CAS: | 2243736-45-8 | | MF: | C18H15Cl2N3O3 | | MW: | 392.24 | | EINECS: | | | Product Categories: | | | Mol File: | 2243736-45-8.mol |  |
| | FB23-2 Chemical Properties |
| density | 1.428±0.06 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO:70.25(Max Conc. mg/mL);179.1(Max Conc. mM) | | form | A solid | | pka | 8.72±0.40(Predicted) | | color | White to light yellow |
| | FB23-2 Usage And Synthesis |
| Uses | FB23-2 is a potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML)[1]. | | in vivo | FB23-2 (2 mg/kg; i.p.; daily; for 10 days) substantially suppresses leukemia progression and prolongs survival[1].
FB23-2 exhibits elimination half-life (rat 6.7 h) and Cmax (rat 2421.3 ng/mL) following intraperitoneal injection (rat 3 mg/kg)[1].
| Animal Model: | NOD/LtSz-scid IL2RG-SGM3 (NSGS) mice, xeno-transplanted with MONOMAC6 AML cells[1] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection, daily, for 10 days | | Result: | Delayed the onset of full-blown leukemic symptoms and significantly prolonged survival by almost doubling the median survival. |
| Animal Model: | Sprague Dawley (SD) rats[1] | | Dosage: | 3 mg/kg (Pharmacokinetic Analysis) | | Administration: | Intraperitoneal injection | | Result: | T1/2 (6.7 hours), Cmax (2421.3 ng/mL). |
| | References | [1] Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10. DOI:10.1016/j.ccell.2019.03.006 |
| | FB23-2 Preparation Products And Raw materials |
|